AI-assisted project content. Not peer reviewed. Evidence may be incomplete; use clinical judgment.
Acetylcholine is a chemical messenger that helps nerves communicate in the brain and throughout the body. Some medicines block part of its action at muscarinic receptors. These are called anticholinergic effects. For one drug, that effect may be the intended treatment; for another, it may be an unwanted side effect.
Anticholinergic burden is the idea of considering several medicines with these effects together. A person might receive one prescription for bladder symptoms, another for mood, and an over-the-counter product for sleep or allergies. Looking at each in isolation can miss a reason to review the full list. The term “burden” does not mean that a website can measure exactly what is happening in that person's brain. It is a prompt to examine medicines and circumstances. A systematic review of burden measures describes substantial differences among scales.
What effects might someone notice?
Possible effects include dry mouth, constipation, blurred vision, and trouble urinating. Confusion or changes in thinking can be especially concerning in a vulnerable older adult. These symptoms have many possible causes, however. A symptom appearing while someone takes a listed medicine is not proof that the medicine caused it. Illness, dehydration, other medicines, and the reason the drug was prescribed all matter. New, severe, or rapidly worsening symptoms deserve clinical assessment.
Why does the whole list matter?
A medication review includes prescriptions, products bought without a prescription, combination cold medicines, supplements, and as-needed doses. A pharmacist or clinician can ask which products are actually used, how often, and at what dose and route. The same ingredient may appear under different brand names or in more than one product. That is one reason an exact ingredient list is more useful than a memory of brand names alone.
Looking at the list does not mean every medicine must be stopped. A drug may provide an important benefit, and stopping it abruptly can cause problems. The useful question is whether each medicine's purpose, benefit, dose, duration, and possible adverse effects still fit the person's situation. The answer is individualized and may involve monitoring rather than changing treatment.
What can a 0–3 scale tell you?
Published scales such as the Anticholinergic Cognitive Burden (ACB), Anticholinergic Risk Scale (ARS), and Anticholinergic Drug Scale (ADS) assign categories using different definitions and evidence. On the ACB scale, 1 indicates possible activity and 2–3 definite activity under that scale's framework. A category belongs to that publication. It is not a measured drug concentration, a percentage chance of dementia, or a clinical prediction for one person. Another scale's “2” may describe something different.
UnifiedACB shows named categories side by side. It does not add unlike scales together. “No rating located” means a value was not found in the current source record; it is not a reported zero. The separate 0–10 UnifiedACB research model has not established a validated whole-drug or medication-list clinical risk score. The Evidence guide explains why a result can remain unassigned.